Drug profile · INN
reslizumab
CINQAERO
reslizumab (CINQAERO) is a interleukin-5 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — reslizumab
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
reslizumab (CINQAERO) is a interleukin-5 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-5 inhibitor
Primary target: Interleukin-5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is reslizumab?
reslizumab (CINQAERO) is a interleukin-5 inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for reslizumab?
CINQAERO is a marketed brand name for reslizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of reslizumab?
reslizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.